Ayala Pharmaceuticals EBITDA
Was ist das EBITDA von Ayala Pharmaceuticals?
EBITDA von Ayala Pharmaceuticals Inc. ist -$15.27
Was ist die Definition von EBITDA?
Das EBITDA ist das Ergebnis eines Unternehmens vor Zinsen, Steuern, Abschreibungen und Amortisationen und ist eine Buchhaltungsgröße, die anhand des Nettoergebnisses eines Unternehmens berechnet wird, bevor Zinsaufwendungen, Steuern, Abschreibungen und Amortisationen abgezogen werden, um die derzeitige operative Ertragskraft eines Unternehmens zu ermitteln.
Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.
EBITDA von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Ayala Pharmaceuticals
Was macht Ayala Pharmaceuticals?
advaxis (nasdaq: adxs) is a late -stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. the advaxis technology, using bioengineered live attenuated bacteria, listeria monocytogenes (lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.
Unternehmen mit ebitda ähnlich Ayala Pharmaceuticals
- Exro Technologies hat EBITDA von -CAD$15.37
- Adial Pharmaceuticals hat EBITDA von -$15.33
- ValOre Metals hat EBITDA von -CAD$15.33
- GEN III Oil hat EBITDA von -CAD$15.30
- Soma Textiles & Industries hat EBITDA von -₨15.28
- BriaCell Therapeutics hat EBITDA von -$15.27
- Ayala Pharmaceuticals hat EBITDA von -$15.27
- Kirin hat EBITDA von -HKD$15.26
- OOOOO Entertainment Commerce hat EBITDA von -CAD$15.23
- Array Technologies hat EBITDA von -$15.22
- HighPeak hat EBITDA von -$15.21
- The Hong Kong Building And Loan Agency hat EBITDA von -HKD$15.18
- Else Nutrition hat EBITDA von -CAD$15.13